Stock screener

MBX

Conviction 94HealthcareScan · Thu, Jun 25, 2026
MBX$50.33+3.99%
ResistanceSupportVol 14Insider sell
63 bars
2
2
Vol MA14 1.08M
Mar 26Apr 14May 1May 19Jun 8Jun 25
MBX Biosciences, Inc.PHARMACEUTICAL PREPARATIONSwww.mbxbio.com
Price50.33
Change+3.99%
Gap+0.31%
Rel volume1.72×
Avg volume916.79K
Avg $ vol34.72M
SMA 2036.57
SMA 5034.32
SMA 20029.27
Price vs 50+46.64%
Price vs 200+71.96%
MA stackbullish
50/200 cross
Supertrendup · 40.27
RSI (14)81
MACD hist1.72
MACD crossbull · 9d
Stoch %K / %D92 / 95
ADX (14)32
+DI / −DI39 / 9
RSI divergence
MACD divergenceBullish
ATR %+6.35%
ADR %8.08%
52w high50.33
52w low9.75
From 52w high+0.00%
Above 52w low+416.47%
New 52w highYes
SqueezeOff
Bollinger width74.64%
%B1.00
Donchian pos91.76%
Donchian high52.34
Donchian low28.00
AVWAP (52w high)50.37
vs AVWAP high-0.08%
AVWAP (52w low)27.58
vs AVWAP low+82.49%
OBV trendUp
Chaikin MF (20)0.38
Today vs 20d1.72×
Avg vol (14d)1.08M
Avg vol (20d)916.79K
Avg $ vol (20d)34.72M
Market cap2.4B
RS 3m (vs SPY)+61.72%
RS 6m (vs SPY)+51.37%
RS line new highYes
Trend template8/8
Technical rank95.6
1 week+21.01%
1 month+58.52%
3 months+73.79%
6 months+44.63%
1 year+355.48%
YTD+64.75%
P/E-27.54
P/B5.47
P/S
P/FCF-29.26
EPS-2.38
Div yield
ROE-19.87%
ROA-19.21%
Debt/Eq
Current30.79
EV/EBITDA
Gross margin
Net margin
Rev growth
EPS growth-40.45%
Price target74.75
Target upside48.52%
Analyst ratingBuy
Institutional115.21%
Ent. value2.35B
Revenue
Net income-23.52M
Gross profit
Free cash flow-81.88M
IndustryPHARMACEUTICAL PREPARATIONS
ExchangeNasdaq
Shares out47.6M
Employees63
ListedFri, Sep 13, 2024
Free float28.64M
Float %60.2%
Short interest4.81M
Days to cover8.5d
Short volume51.4%
Squeeze score77 / 100
Next earningsThu, Aug 6, 2026 (42d)
EPS forecast−$0.68 · 3 est
Last EPS vs est−$0.51 vs −$0.62
Last surprise+17.7% beat
Setup gradeA+
Conviction94 / 100
Pattern quality
Tech rank95.6 / 100
Group rank50 / 100
Status laneNo active setup
Setup direction
Pattern family
Resistance39.46
Support28.41
Days since event
Candle confirm
News sentiment

Financials as of Tue, Mar 31, 2026 · quarterly.

Congress activity

Disclosed STOCK Act trades in MBX

All disclosures →
No recent disclosed trades by Congress in MBX. STOCK Act filings can lag the trade by up to 45 days.

Insider activity

SEC Form 4 transactions in MBX · 8 buys

InsiderSideShares
Hoerter Steven L.
Director · Stock option (right to buy) · 2026-06-04
Grant12.5K
Mathers Edward T
Director · Stock option (right to buy) · 2026-06-04
Grant12.5K
Ryder Steven
Director · Stock option (right to buy) · 2026-06-04
Grant12.5K
Hoerter Steven L.
Director · Common Stock · 2026-06-04
Other
Pescovitz Ora H.
Director · Common Stock · 2026-06-04
Other
Pescovitz Ora H.
Director · Stock option (right to buy) · 2026-06-04
Grant12.5K
Stelzer Laurie
Director · Stock option (right to buy) · 2026-06-04
Grant12.5K
Heron Patrick J
Director · Stock option (right to buy) · 2026-06-04
Grant12.5K
Aynechi Tiba
Director · Stock option (right to buy) · 2026-06-04
Grant12.5K
Azoulay Salomon
Chief Medical Officer · Common Stock · 2026-05-08
Exercise55K

SEC filings

EDGAR filings in MBX · 5 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, cancel in one click.

Start free — 7-day full access →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.